Power wheelchair — group 2 denied for failing step therapy by UnitedHealthcare?

Under UnitedHealthcare's Commercial medical policy, mobility devices including manual wheelchairs, electric wheelchairs, transfer chairs, scooters/power-operated vehicles (POV), canes, and walkers are a covered health care service when medically necessary. The policy aligns with CMS LCD L33789, which establishes that the beneficiary must have a mobility limitation that significantly impairs his/her ability to participate in one or more mobility-related activities of daily living (MRADLs) such as toileting, feeding, dressing, grooming, and bathing in customary locations in the home — a limitation that prevents the beneficiary from accomplishing an MRADL entirely, places the beneficiary at heightened risk of morbidity or mortality, or prevents completing an MRADL within a reasonable time frame ; additionally, the mobility limitation cannot be sufficiently and safely resolved by an appropriately fitted cane or walker, and the beneficiary does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. Use of a power wheelchair must significantly improve the beneficiary's ability to participate in MRADLs and the beneficiary will use it in the home (for severe cognitive/physical impairments, participation in MRADLs may require caregiver assistance), and the beneficiary has not expressed an unwillingness to use a power wheelchair in the home. For a Group 2 standard PWC, a Group 2 PWC (K0820, K0821, K0822, K0823, K0824, K0825, K0826, K0827, K0828, K0829) is covered if all of the coverage criteria (a)-(e) for a PWC are met and the wheelchair is appropriate for the beneficiary's weight. For a Group 2 Single Power Option PWC, all coverage criteria (a)-(e) must be met, plus the beneficiary meets coverage criteria for a power tilt or recline seating system OR requires a drive control interface other than a hand or chin-operated standard proportional joystick (examples include head control, sip and puff, switch control) , and a specialty evaluation must be performed by a licensed/certified medical professional (PT, OT, or practitioner with rehab wheelchair training) with no financial relationship with the supplier, and the wheelchair must be provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) with direct, in-person involvement in the wheelchair selection. DME has a reasonable useful lifetime (RUL) of 5 years , and payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary.

- **Document MRADL impact in detail**: Provide a clinician note specifying which MRADLs (toileting, feeding, dressing, grooming, bathing) the patient cannot complete or completes only with heightened morbidity/mortality risk, directly mapping to the LCD L33789 definition of a qualifying mobility limitation . - **Stepwise rule-out of lesser devices**: Submit PT/OT documentation explaining why a cane, walker, and optimally-configured manual wheelchair each fail — addressing strength, endurance, ROM, coordination, pain, or upper-extremity deformity per the LCD's enumerated upper-extremity assessment factors (strength, endurance, range of motion, coordination, pain, deformity or absence of one or both upper extremities) . - **Provide compliant face-to-face and WOPD**: Attach the dated face-to-face mobility examination note and the signed Standard Written Order before delivery; cite Final Rule 1713's requirement of a face-to-face encounter and Written Order Prior to Delivery as satisfied. - **Include RESNA ATP and independent specialty evaluation**: For Group 2 Single Power Option chairs, include both the ATP credential attestation and the independent PT/OT specialty evaluation, satisfying the requirement that a licensed PT/OT with no financial relationship to the supplier perform the specialty evaluation and that a RESNA-certified ATP have direct involvement in wheelchair selection . - **Demonstrate in-home use**: Document home assessment showing adequate access between rooms and maneuvering space, and explicitly state the device will be used in the home to meet the requirement that the beneficiary's home provides adequate access and that the power wheelchair will significantly improve the beneficiary's ability to participate in MRADLs in the home . - **Justify Group 2 over Group 1**: If denied as needing only a Group 1, document the patient's weight against capacity limits or, for Single Power Option, the medical necessity of power tilt/recline (e.g., pressure ulcer risk, inability to perform a functional weight shift) or alternative drive control interface per LCD L33789 Group 2 Single Power Option criteria including need for non-standard drive control such as head control, sip and puff, or switch control . - **Replacement vs. repair**: For replacement requests, document the 5-year RUL and that the existing chair cannot be repaired or no longer meets the patient's needs, citing the 5-year reasonable useful lifetime standard and UHC's allowance for upgrades when the member's condition changes (e.g., impaired function necessitates an upgrade to a power wheelchair from a manual one) .

## Why UnitedHealthcare flags Group 2 PWCs for step therapy

When UnitedHealthcare denies a K0820–K0829 Group 2 power wheelchair on step-therapy grounds, the issue is almost never whether the beneficiary needs a mobility device — it is whether the submitted documentation proves every rung of the CMS Mobility Assistive Equipment (MAE) algorithm embedded in LCD L33789 (the DME MAC policy UHC's Mobility Devices, Options, and Accessories Commercial Medical Policy mirrors verbatim) has been climbed. UHC reviewers will deny Group 2 if the chart does not affirmatively rule out (1) cane/walker, (2) manual wheelchair, (3) POV/scooter, and (4) in some reviewer practice, a Group 1 PWC — even though the LCD does not require a sequential trial-and-fail of each device, only a clinically reasoned exclusion of each.

That distinction is the appeal. Under 29 CFR §2560.503-1(g) UHC must give the specific clinical rationale and the internal rule applied; a boilerplate "lesser device not ruled out" letter is facially deficient and is the lever to demand a full reissue with the reviewer's credentials and the exact MAE-algorithm step that failed. 29 CFR §2590.712 NQTL parity is not in play here, but the ERISA disclosure rule plus Wit v. United Behavioral Health (N.D. Cal. 2019, aff'd in relevant part 9th Cir. 2023) is — Wit's holding that Optum/UHC cannot substitute restrictive internal criteria for generally accepted clinical standards translates directly: the AAPMR/RESNA consensus is that PWC group selection is driven by seating/control needs, not a forced Group 1 trial that exposes a sip-and-puff or tilt-dependent user to harm.

Build the appeal around the ATP/LCMP packet. UHC's policy requires a specialty evaluation by a PT, OT, or physician with rehab-wheelchair training who has no financial relationship with the supplier, plus direct in-person involvement of a RESNA-certified ATP. Submit (a) the LCMP specialty evaluation explicitly addressing why a cane/walker, MWC, POV, and Group 1 PWC each fail the MRADL test in the home — cite specific doorways, transfer surfaces, upper-extremity MMT grades, endurance data; (b) the ATP home assessment; (c) the treating practitioner's face-to-face mobility exam dated within 6 months; (d) HCPCS-level justification for Group 2 features (weight capacity, programmable electronics, expandability). For Single Power Option configurations (K0835–K0843), document the tilt/recline indication or alternative drive control need separately.

Tactical closer: file the internal appeal through the UHC Provider Portal Reconsideration queue (not the OptumRx PA channel — DME is UHC medical, not PBM-routed), demand peer-to-peer with a physiatrist or PM&R-trained MD (not a generalist), and if upheld, push immediately to external IRO review under your state's NAIC-model statute. For fully-insured ERISA plans, also invoke §503-1(h) to toll the 180-day clock until UHC produces the reviewer's name and the LCD-aligned criteria worksheet — that disclosure alone often surfaces a reviewer who applied an outdated MP version and forces overturn on remand.